http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#Head http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#assertion http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#provenance http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#pubinfo http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#assertion http://purl.obolibrary.org/obo/DOID_1040 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1040 http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB09054 http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association http://www.w3.org/2000/01/rdf-schema#label zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed chronic lymphocytic leukemia cll in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co morbidities 1 1 relapsed follicular b cell non hodgkin lymphoma fl in patients who have received at least two prior systemic therapies 1 2 relapsed small lymphocytic lymphoma sll in patients who have received at least two prior systemic therapies 1 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of any patient 1 1 1 2 1 3 zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl 1 2 accelerated approval was granted for fl and sll based on overall response rate improvement in patient survival or disease related symptoms has not been established continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials zydelig is indicated in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia cll for whom rituximab alone would be considered appropriate therapy due to other co morbidities limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with cll zydelig is indicated for the treatment of patients with relapsed follicular b cell non hodgkin lymphoma fl who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 2 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with fl zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma sll who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with sll http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB09054 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#provenance http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#pubinfo http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#sig http://purl.org/nanopub/x/hasSignature bXMzOf/OTp+iPy9keH4ViShmSIn1R3f/b5cn4jgYiHRlnWWQBqiOvOpF1ZjOTc2iwt3ohRUf891FknMRP4zEWo6StoWfSwxecoUp2mcjfAVEkB6VsW43jvX/lUXO1vS/WkLWFnrmjc53CK21X1muncMRunPZvvCNZLiDh97Scsw= http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 http://purl.org/dc/terms/created 2021-06-12T14:32:34.213+02:00 http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAKPZmCZwmP83KszoeZyTHeqD3t4MVxR47dALSYKjmy48 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs